- £3.62bn
- £4.61bn
- $3.16bn
- 83
- 60
- 42
- 71
REG - Hikma Pharmaceutical - Block listing Interim Review
AnnouncementREG - Hikma Pharmaceutical - Annual Financial Report and Notice of AGM
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Final Results
AnnouncementREG - Hikma Pharmaceutical - Notice of Results
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Outcome of Audit Tender Process
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - 2024 Annual General Meeting Update Statement
AnnouncementREG - Hikma Pharmaceutical - Block listing Interim Review
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma completes Xellia acquisition
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Half-year Report
AnnouncementREG - Hikma Pharmaceutical - Director Declaration
AnnouncementREG - Hikma Pharmaceutical - Notice of Results
AnnouncementREG - Hikma Pharmaceutical - Total Voting Rights
AnnouncementREG - Hikma Pharmaceutical - Director Declaration
AnnouncementREG - Hikma Pharmaceutical - Hikma acquires Xellia’s assets
Announcement